Bayer Corporation, sued along with other pharmaceutical companies in a class action for allegations of pay-for-delay contracts and non-compete agreements, has partially settled with plaintiffs for $74 million, though the additional defendants have yet to reach a similar agreement.
Bayer, along with Barr, Hoechst Marion Roussel, Watson Pharmaceuticals and The Rugby Group, were brought to court for so-called pay-for-delay agreements, alleged to have paid the generic makers of an antibiotic called Cipro to delay sales; the drug companies are refuting the claims.
Members of the class involve buyers of Cipro within California between January 8, 1977 and October 31, 2004.
Full Content: PR Newswire
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI